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Background: This study aimed to determine the relationship between CK19 mRNA copy number in
sentinel lymph nodes (SLN) assessed by one-step nucleic acid ampliﬁcation (OSNA) technique, and non-
sentinel lymph nodes (NSLN) metastization in invasive breast cancer. A model using total tumor load
(TTL) obtained by OSNA technique was also constructed to evaluate its predictability.
Methods: We conducted an observational retrospective study including 598 patients with clinically T1-
T3 and node negative invasive breast cancer. Of the 88 patients with positive SLN, 58 patients fulﬁll the
inclusion criteria.
Results: In the analyzed group 25.86% had at least one positive NSLN in axillary lymph node dissection.
Univariate analysis showed that tumor size, TTL and number of SLN macrometastases were predictive
factors for NSLN metastases. In multivariate analysis just the TTL was predictive for positive NSLN (OR
2.67; 95% CI 1.06e6.70; P ¼ 0.036). The ROC curve for the model using TTL alone was obtained and an
AUC of 0.805 (95% CI 0.69e0.92) was achieved. For TTL >1.9  105 copies/mL we got 73.3% sensitivity,
74.4% speciﬁcity and 88.9% negative predictive value to predict NSLN metastases.
Conclusion: When using OSNA technique to evaluate SLN, NSLN metastases can be predicted intra-
operatively. This prediction tool could help in decision for axillary lymph node dissection.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
Sentinel lymph node (SLN) biopsy have become the standard
technique for determining axillary nodal involvement in patients
with early-stage breast cancer who are clinically negative.
Identifying the SLN as non-metastatic spares unnecessary axil-
lary lymph node dissection (ALND) and therefore decreases the
chances of signiﬁcant co-morbidities [1].
Intraoperative diagnosis of positive SLN can allow ALND in the
same surgical procedure when criteria are present, thus avoiding a
second surgery to treat the axilla and decreasing the patient's
associated discomfort and institutional costs [2,3].
The one-step nucleic acid ampliﬁcation (OSNA, Sysmex, Kobe,
Japan) assay is a molecular method that measures the quantity of
cytokeratin (CK)-19mRNA (aduct epithelial cellmarker that is highlytro Hospitalar Lisboa Central,
s).expressed in more than 95% of breast cancers) in axillary lymph
nodes [4]. Cutoff values were deﬁned to classify macrometastases
(more than 5000 copies/mL),micrometastases (250e5000 copies/mL)
and negative nodes (fewer than 250 copies/mL) [5].
Combined analysis of nine studies that compared OSNA with
histopathology demonstrated high concordance between both
methods (96%) and reported high sensitivity, speciﬁcity and nega-
tive predictive value for OSNA [2]. As the OSNA assay is essentially
an automated procedure, it has clear advantages in standardization,
reproducibility and objectivity.
There is so far no clear consensus on how to approach ALND.
Several studies have identiﬁed predictors of metastases to non-
sentinel lymph nodes (NSLNs), to select patients who can be
spared ALND, and different nomograms have been proposed to
select patients who would not beneﬁt from ALND.
Recently, the American College of Surgeons Oncology Group
(ACOSOG) Z0011 trial deﬁned a select cohort of patients with
positive SLNs in whom a complete ALND may be safely omitted [6].
However, many patients still require prediction of non-SLN
metastases.
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to study the relationship between CK19 mRNA copy number and
the NSLN metastization.
Ohi et al. (2012) and Osako et al. (2013) demonstrated that the
NSLN macrometastatic rate increased in proportion to CK19 mRNA
copy numbers [7,8]; Ohi et al. veriﬁed that the CK19 mRNA copy
number in SLN is the most important predictive factor of NSLN
metastases, and that higher copy numbers are strongly associated
with four or more axillary lymph node metastases [7].
Other groups also evaluated the correlation between the total
tumor load (TTL) in SLN and additional NSLN metastases [9,10].
Banerjee et al. (2014), in a small subgroup of 45 women who had
undergone ALND, found that using the CK19 mRNA copy number
alone resulted in an AUC of 0.828, which indicates that OSNA is
more useful than nomograms in predicting the risk of NSLN
metastasis [2].
This study aimed to determine the relationship between CK19
mRNA copy numbers and subsequent NSLN metastization, and to
determine the TTL intraoperatively as a threshold above which
metastases are expected, to support surgeons' oncological de-
cisions regarding the need to perform ALND.2. Materials and methods
This observational retrospective study was conducted between
October 2010 and December 2014, and initially enrolled 598
women with invasive breast cancers. Inclusion criteria were pa-
tients whose disease had been assessed clinically and ultrasono-
graphically as node-negative and at tumor stage cT1e3, and who
had undergone intraoperative SLN evaluation by OSNA. We
excluded patients who had received neoadjuvant treatment, whose
biopsies showed CK19-negative tumors, or those who did not un-
dergo ALND. Of the 598 patients, 88 had positive SLNs. Of these 88,
61 had been analyzed by OSNA, three of whom were excluded
because they had not undergone ALND. Finally, 58 valid patients
were studied. Data collected included age, tumor size, grade, his-
tological subtype, estrogen and progesterone receptor status, HER2
status, Ki67, lymphovascular invasion, multifocality, total numberTable 1
Patient's characteristics and comparison of negative versus positive NSLN.
Negative NSLN (n ¼ 43
Age e years (mean ± SD) 57.10 ± 11.09
Histologic type
Invasive ductal carcinoma 35
Invasive þ ductal carcinoma in situ 3
Invasive lobular carcinoma 5
Invasive papillary carcinoma 0













SLN number (mean ± SD) 2.23 ± 1.15
SLN macrometastases (mean ± SD) 1.19 ± 0.55
NSLN resected (mean ± SD) 11.86 ± 6.11
TTL - log (mean ± SD) 4.65 ± 0.84
ER: estrogen receptors; PR: progesterone receptors; HER2: human epidermal growth fa
total tumor load.of SLNs and non-SLNs, type of surgery, the number of positive and
negative non-SLNs, and CK19 mRNA copies.
SLNs were detected using radioisotopes and blue dye, and sent
for pathological analysis. When macrometastases were found
during intraoperative evaluation, patients underwent level II
ALNDs. Depending on patient and tumor characteristics, lumpec-
tomies or mastectomies were also performed.
OSNA evaluations were completed for the isolated SLNs. The
OSNA assay procedure has already been described in detail [4]. The
analysis result included the number of CK19 mRNA copies per mL.
These copy numbers were used semi-quantitatively to characterize
node involvement; those with <250 copies/mL were considered
non-metastatic, 250e5000 copies/mL as having micrometastases,
and >5000 copies/mL as having macrometastases.
NSLNs obtained from ALND were studied after being processed
by histopathologic methods. Immunohistochemical staining was
not used.2.1. Statistical analysis
Data were evaluated descriptively, with frequencies used for
categorical variables and medians for continuous variables. Chi-
square and ANOVA tests were used to compare positive and
negative NSLNs. We conducted univariate and multivariate ana-
lyses, from which non-signiﬁcant variables (P > 0.05) were drop-
ped. Logistic regression was used to assess the capacity of the
studied variables to identify positive NSLNs.
The TTL variable was studied using area under the receiver
operating characteristic (ROC) curve (AUC), after log transformation
to avoid nonlinearities. The statistical analyses were carried out in
SPSS 20.0 for Windows and MedCalc 15.8.3. Results
3.1. Patients' characteristics
Of the 58 patients with positive SLNs who were analyzed by
OSNA in this study, 15 (25.86%) were found to have positive nodes) Positive NSLN (n ¼ 15) P value



















2.60 ± 1.06 0.282
1.80 ± 0.68 0.001
12.80 ± 5.36 0.599
5.54 ± 0.71 0.000
ctor receptor 2; SLN: sentinel lymph nodes; NSLN: non-sentinel lymph nodes; TTL:
Table 2









Age (years) 0.99 (0.94e1.05) 0.711
Tumor size (mm) 1.08 (1.00e1.16) 0.047 1.06 (0.98e1.15) 0.168
Log TTL (copies/mL) 3.56 (1.57e8.09) 0.002 2.67 (1.06e6.70) 0.036
SLN macrometastases 4.64 (1.55e13.92) 0.006 2.63 (0.94e7.36) 0.066
Histologic type
Invasive ductal carcinoma 1 0.974
Invasive þ ductal carcinoma in situ 0.97 (0.09e10.26)
Invasive lobular carcinoma 0.58 (0.06e5.51)





Lymphovascular invasion (yes vs no) 1.60 (0.45e5.74) 0.471
ER (positive vs negative) 2.33 (0.26e21.17) 0.451
PR (positive vs negative) 6.28 (0.75e52.90) 0.091
HER2 (positive vs negative) 0.71 (0.13e3.94) 0.699
Multifocality (yes vs no) 2.78 (0.53e14.48) 0.226
ER: estrogen receptors; PR: progesterone receptors; HER2: human epidermal growth factor receptor 2; SLN: sentinel lymph nodes; TTL: total tumor load.
Fig. 1. ROC Curve using TTL variable as predictor of NSLN metastases.
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tumor size of 21.79 mm, mean SLN number of 2.31, and 1.36 mac-
rometastases. The mean TTL was 5.86  105 copies/mL. More
detailed patients' characteristics, stratiﬁed by positive or negative
NSLN, are shown in Table 1.
3.2. Univariate and multivariate analyses
In univariate analysis, we considered age, tumor size, TTL, SLN
macrometastases, histologic type, histological tumor grade, lym-
phovascular invasion, ER, PR, HER2 and multifocality; and found
tumor size, TTL and number of SLN macrometastases to be pre-
dictive factors of NSLN metastases (P < 0.05; Table 2).
In multivariate analysis, TTL was the only independent predictor
of NSLN metastases (odds ratio [OR]: 2.67; 95% conﬁdence interval
[CI]: 1.06e6.70; P ¼ 0.036; Table 2). Both tumor size and number of
SLN macrometastases were signiﬁcantly associated with additional
NSLN metastases in univariate analysis, but not in multivariate
analysis (OR: 1.06; 95% CI: 0.98e1-15; P ¼ 0.168 and OR: 2.63; 95%
CI: 0.94e7.36; P ¼ 0.066, respectively).
Intraoperative TTL assessment by OSNA was further studied by
ROC curve. The AUC of TTL/log TTL was 0.805 (95% CI 0.69e0.92;
P < 0.05; Fig. 1). We then used the ROC curve to choose a cutoff
point for TTL at log TTL >5.28 or TTL >1.9  105 copies/mL, which
gave 73.3% sensitivity, 74.4% speciﬁcity, and 88.9% negative pre-
dictive value for NSLN metastases. In this sample there were 15
patients with NSLN metastases, 11 of whom had TTL >1.9  105
copies/mL.
4. Discussion
SLNs are the ﬁrst axillary nodes to receive lymphatic ﬂow from
primary tumors and themost likely to harbor tumor cells. If SLN has
no metastases, ALND can be safely avoided [1]. However, if the SLN
is positive for macrometastases, ALND is the standard procedure,
even though more than half of these patients have no NSLN me-
tastases. In our study, only 25.86% of patients with positive SLNs
had NSLN metastases.
Several prediction models for NSLN metastases in patients with
positive SLNs have been developed, but most are based on post-
operative histological ﬁndings, and are therefore not helpful for
intraoperative decision making.
OSNA assay is a molecular-based intraoperative detectionmethod for SLN metastases that has several advantages over frozen
sections; it is a fast, standardized technique in which the entire
lymph node is examined and provides quantitative results [2].
In this study, univariate analysis showed that tumor size,
number of SLN macrometastases and CK19 mRNA copies (TTL)
determined by OSNA assay were signiﬁcantly associated with non-
SLN metastases. These results are in line with other studies [9,10].
However, in multivariate analysis, TTL was the only variable with a
signiﬁcant association that could be used intraoperatively.
Reportedly, TTL can be used as a predictor for non-SLN metas-
tases [9,10]. We studied the prediction model with TTL using the
ROC curve, which had good discrimination acuity (AUC ¼ 0.805) in
this group of patients. At a TTL cutoff of >1.9  105 copies/mL, there
was 73.3% sensitivity and 74.4% speciﬁcity in predicting NSLN me-
tastases. This cutoff was calculated considering a low false positive
rate to avoid hypothetically unnecessary ALND in post Z0011 era.
Espinosa-Bravo et al. (2013) also reported similar results [9].
After the results of the ACOSOG Z0011 trial were reported, the
standard practice of ALND in the presence of positive SLNs was
C. Nabais et al. / The Breast 32 (2017) 33e3636questioned. This trial indicated that ALND has no signiﬁcant impact
on either disease-free or overall survival of patients with SLN me-
tastases, but these results are only applicable to patients who met
the study inclusion criteria (fewer than three SLN metastases,
treatment with breast-conserving surgery, radiation therapy and
systemic therapy) [6].
In patients for whom the results of the Z0011 are not applicable,
prediction models for NSLN metastases are still helpful for ALND
surgical decisions. The current predictor model using TTL can be
intraoperatively valuable, as a simple, fast and accurate method of
assessing the probability of NSLN.
Our study has the limitations of being retrospective with a small
sample size. The clinical implications of TTL in how we surgically
manage patients are therefore limited. Larger prospective studies
are needed to determine the prognostic implications.
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